Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2014-08-19 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2014年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2014 半年度财务报告" which translates to "2014 Half-Year Financial Report". It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and shareholders' equity changes for the period January 1, 2014 to June 30, 2014. The presence of comprehensive financial data and analysis for a half-year period clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it includes actual financial statements rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2014
2014-08-19 Chinese
2014年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2014 半年度报告摘要' which translates to '2014 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes shareholder information and management discussion and analysis. The document is about 3575 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. The content matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2014
2014-08-19 Chinese
第五届董事会第九次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing SL Pharmaceutical Co., Ltd. It details the approval of the 2014 semi-annual report and a related investment decision. The text includes voting results and meeting procedural details but does not contain the actual semi-annual financial report or substantive financial data. It references the semi-annual report and provides links to where the full report can be found, indicating this document is an announcement of the board's resolutions rather than the report itself. The document length is short (1776 characters), consistent with an announcement rather than a full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and approvals.
2014-08-19 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 90% confidence The document is a special statement and independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding the company's external guarantees and the use of company funds by controlling shareholders and related parties. It references regulatory notices from the China Securities Regulatory Commission and discusses compliance with laws and internal management systems. The document is relatively short (711 characters) and does not contain financial statements or detailed financial data. It is a regulatory compliance statement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit-like oversight and compliance verification regarding guarantees and related party transactions. H1 2014
2014-08-19 Chinese
2014年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "北京双鹭药业股份有限公司 2014 年半年度报告全文" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2014 Semi-Annual Report Full Text." It contains detailed financial data, including revenue, net profit, cash flow, investment activities, and other financial metrics for the period January 1, 2014 to June 30, 2014. The document includes sections such as company overview, accounting data and financial indicators summary, board of directors report, investment status analysis, and financial statements. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year (half-year). This matches the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, but a full report with detailed financials and management discussion. Therefore, the correct classification is IR with high confidence. H1 2014
2014-08-19 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing SL Pharmaceutical Co., Ltd. regarding an external investment of 5 million RMB to acquire 5% shares in Beijing Zhongguanke City Technology Co., Ltd. It includes details about the transaction, the parties involved, financial data of the investee company, and the purpose and risks of the investment. The document is a formal disclosure of a capital investment transaction, not a financial report, earnings release, or management discussion. It does not contain comprehensive financial statements or detailed financial analysis but rather focuses on the investment transaction details. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2014-08-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.